SSelectStock

THYROCAREThyrocare Technologies Limited

Healthcare · Diagnostics & Research · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

549.70
1.43%
60Decent

Mkt Cap
₹8,748 Cr
P/E
49.8
P/B
14.9
Div Yield
1.71%
52W High
₹662.00
52W Low
₹338.15

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)8,747.80
P/E49.75
P/B14.94
PEG1.54
ROE %27.80
ROCE %32.20
Debt / Equity0.09
EPS11.05
Revenue Growth %24.30
Profit Growth %31.80
Dividend Yield %1.71
Promoter Holding %51.18
FII Holding %20.16
DII Holding %
Beta0.47

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on THYROCARE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

HOLDConviction 59%

The picture

  • Revenue growth: 24.3% YoY
  • Profit growth: 31.8% YoY
  • ROE: 27.8%
  • Price vs SMA200: above
  • Golden cross setup: SMA50 above SMA200
  • 3-month vs NIFTY: +6.3% relative

Bull case

  • Revenue growth: 24.3% YoY
  • Profit growth: 31.8% YoY
  • ROE: 27.8%
  • Price vs SMA200: above

Bear case

  • RSI: 39
  • MACD: bearish
  • 1-month return: -9.3%
  • 1-month vs NIFTY: -5.2% relative

Key risks

  • RSI: 39
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹549.70
Stop Loss
₹539.55
risk 1.8%
Target 1 (1.5R)
₹564.93
+2.8%
Target 2 (3R)
₹580.15
+5.5%
Support (20d)
₹545.00
Resistance (52w)
₹662.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹10.15/share
ATR (volatility)
₹18.91
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹18.91). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental92
Technical37
Momentum51
Risk (safety)59

Peers — Healthcare

GKSL 1.23%
79
NEPHROPLUS 2.42%
74
KOVAI 1.41%
73
SAILIFE 0.38%
73
METROPOLIS 1.70%
73
VIJAYA 0.21%
72